Coloplast A/S (COLO B)

Basic

  • Market Cap

    DKK 172.4B

  • EV

    DKK 191.06B

  • Shares Out

    224.66M

  • Revenue

    DKK 24.5B

  • Employees

    15,692

Margins

  • Gross

    66.64%

  • EBITDA

    30.89%

  • Operating

    27.96%

  • Pre-Tax

    24.59%

  • Net

    19.52%

  • FCF

    13.09%

Returns (5Yr Avg)

  • ROA

    21.93%

  • ROE

    54.65%

  • ROCE

    54.85%

  • ROIC

    29.91%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    DKK 817.56

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    DKK 113.74

  • Earnings (Dil)

    DKK 22.2

  • FCF

    DKK 14.88

  • Book Value

    DKK 77

Growth (CAGR)

  • Rev 3Yr

    9.73%

  • Rev 5Yr

    8.29%

  • Rev 10Yr

    7.73%

  • Dil EPS 3Yr

    4.12%

  • Dil EPS 5Yr

    4.17%

  • Dil EPS 10Yr

    5.83%

  • Rev Fwd 2Yr

    10.29%

  • EBITDA Fwd 2Yr

    11.39%

  • EPS Fwd 2Yr

    11.39%

  • EPS LT Growth Est

    19%

Dividends

  • Yield

    —

  • Payout

    94.57%

  • DPS

    DKK 21

  • DPS Growth 3Yr

    5.27%

  • DPS Growth 5Yr

    13.81%

  • DPS Growth 10Yr

    11.61%

  • DPS Growth Fwd 2Yr

    2.89%

Select a metric from the list below to chart it

Sep '14
Sep '16
Sep '18
Sep '20
Sep '22
Metric
Sep '14
Sep '15
Sep '16
Sep '17
Sep '18
Sep '19
Sep '20
Sep '21
Sep '22
Sep '23

Total Revenues

17,939.0

18,544.0

19,426.0

22,579.0

24,500.0

Total Revenues % Chg.

9.1%

3.4%

4.8%

16.2%

8.5%

Cost of Goods Sold, Total

5,743.0

5,932.0

6,113.0

7,050.0

8,172.0

Gross Profit

12,196.0

12,612.0

13,313.0

15,529.0

16,328.0

Selling General & Admin Expenses, Total

5,963.0

6,079.0

6,247.0

7,802.0

8,633.0

Stock-Based Compensation

7.0

7.0

2.0

-2.0

-1.0

R&D Expenses

692.0

708.0

755.0

866.0

872.0

Other Operating Expenses

-42.0

-29.0

-48.0

-56.0

-25.0

Other Operating Expenses, Total

6,620.0

6,765.0

6,956.0

8,610.0

9,479.0

Operating Income

5,576.0

5,847.0

6,357.0

6,919.0

6,849.0

Interest Expense, Total

-6.0

-30.0

-25.0

-172.0

-638.0

Interest And Investment Income

19.0

8.0

11.0

39.0

111.0

Net Interest Expenses

13.0

-22.0

-14.0

-133.0

-527.0

Income (Loss) On Equity Invest.

—

—

—

—

—

Currency Exchange Gains (Loss)

2.0

-338.0

114.0

-134.0

-178.0

Other Non Operating Income (Expenses)

-168.0

-32.0

-31.0

-66.0

-78.0

EBT, Excl. Unusual Items

5,423.0

5,455.0

6,426.0

6,586.0

6,066.0

Restructuring Charges

-43.0

—

—

—

—

Merger & Related Restructuring Charges

—

—

—

-171.0

-118.0

Gain (Loss) On Sale Of Assets

16.0

—

-4.0

-7.0

-3.0

Insurance Settlements

—

—

—

—

—

Legal Settlements

-400.0

—

-200.0

-300.0

-200.0

Other Unusual Items

32.0

11.0

11.0

19.0

280.0

EBT, Incl. Unusual Items

5,028.0

5,466.0

6,233.0

6,127.0

6,025.0

Income Tax Expense

1,155.0

1,269.0

1,408.0

1,421.0

1,242.0

Earnings From Continuing Operations

3,873.0

4,197.0

4,825.0

4,706.0

4,783.0

Net Income

3,873.0

4,197.0

4,825.0

4,706.0

4,783.0

Net Income to Common Incl Extra Items

3,873.0

4,197.0

4,825.0

4,706.0

4,783.0

Net Income to Common Excl. Extra Items

3,873.0

4,197.0

4,825.0

4,706.0

4,783.0

Total Shares Outstanding

212.4

212.7

212.8

212.3

224.7

Weighted Avg. Shares Outstanding

212.3

212.6

212.8

212.5

215.4

Weighted Avg. Shares Outstanding Dil

213.1

213.3

213.2

212.8

215.5

EPS

18.2

19.7

22.7

22.1

22.2

EPS Diluted

18.2

19.7

22.6

22.1

22.2

EBITDA

6,194.0

6,450.0

6,897.0

7,544.0

7,568.0